All In Biotech

Drug Trial Radar · NCT06791434

Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment

Investigating Dry Needling as an Add-on Therapy to Conventional Treatment for Myofascial Low Back Pain: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Aug 30, 2024

Primary completion

Aug 26, 2025

Study completion Aug 26, 2025

Sponsor

Lead sponsor
Dr. Vishwanath Karad MIT World Peace UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed clinical study aims to evaluate the effectiveness and safety of adding Dry Needling (DN) to Conventional Treatment (CT) for patients with Myofascial Low Back Pain (MLBP). MLBP is a widespread musculoskeletal condition that causes localized pain, muscle tenderness, and functional limitations, significantly affecting the quality of life and productivity of those affected. Conventional Treatment for MLBP typically combines pharmacotherapy (e.g., NSAIDs, muscle relaxants) and physiotherapy. Dry Needling, an emerging treatment that targets myofascial trigger points with fine needles, has demonstrated promise in relieving pain and improving functional outcomes. However, no study has yet evaluated the combined effects of CT and DN. This randomized, open-label, controlled trial will involve 140 patients (70 per group) and compare the effects of CT alone versus CT combined with DN. The primary objective is to assess the change in pain intensity, while secondary objectives include improvements in pressure pain threshold, range of motion, disability, quality of life, sleep, anxiety, and depression scores. Safety will also be assessed based on adverse events and vital sign changes. The study will span 24 weeks, with 11 scheduled visits for each participant. Data analysis will be conducted to determine the added benefit of DN as an adjunctive therapy to CT, with the ultimate goal of improving treatment strategies and patient outcomes for MLBP.

Conditions

  • Low Back Pain

Interventions

  • Fixed Dose Combination "Etoshine MR" tabletsDrug

    Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg

  • Dry needlingProcedure

    Thin needle insertion

  • PhysiotherapyOther

    Exercises

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Pain Intensity using Numeric Pain Rating Scale (NPRS)Time frame: Screening, Day 0, 3, 7, 10, 14, 28, 56, 84, 168

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sigma Spine and Pain Clinic

    Pune, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.